Underestimation of renal risk in cardiology clinics. RICAR study;Infravaloración del riesgo renal en consultas de cardiología. Estudio RICAR

Nefrologia

Volumn 28, Issue 6, 2008, Pages 621-626

  Bertomeu Martinez V ^a   Gonzalez Juanatey J R ^b   Bertomeu Gonzalez V ^a   Facila L ^c   Mazon P ^c   Quiles, J ^a   Filozof, C ^d   Morillas, P ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c Hospital Provincial de Castellon   (Spain)

^d Bristol Myers Squibb   (Spain)

Author keywords

Arterial hypertension; Glomerular filtration rate; Microalbuminuria; Vascular risk

Indexed keywords

AGED; ALBUMINURIA; ARTICLE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY;

AGED; ALBUMINURIA; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; RETROSPECTIVE STUDIES;

EID: 59049105385     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL y cols. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-15.
3. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM y cols. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn study. Arterioscler Thromb Vasc Biol 1999; 19: 617-24.
4. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B y cols.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-6.
5. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ y cols. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26.
6. Chobanian A, Bakris GL, Black HR, Cushman W, Green LA, Izzo JL y cols. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-72.
7. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL y cols.; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G y cols. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
9. Lehnert H, Bramlage P, Pittrow D, Kirch W. Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment: an observational study in 38016 patients in primary care. Clin Drug Investig 2004; 24: 217-25.
10. Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
12. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med 2003; 139: 137-47.
13. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE y cols. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005; 45; 198-202.
14. González-Juanatey JR, Alegría E, Zamorano JL, Bertomeu V, Velasco 0, Larrondo I, Honorato J. Albuminuria y riesgo cardiovascular. Estudio KORAL-CARDIO. Nefrología 2006; 26: 426-432.
15. Derchi LE, Leoncini G, Parodi D, Viazzi F, Martinoli C, Ratto E, et al. Mild Renal Dysfunction and Renal Vascular Resistance in Primary Hypertension. Am J Hypertens 2005;18: 966-71.
16. De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-5.
17. Slowik A, Turaj W, Iskra T, Strojny J, Szczudlik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovasc Dis 2002; 14: 15-21.
18. Redón J, Cea-Calvo L, Lozano JV, Fernández-Pérez C, Navarro J, Bonet A, González-Esteban J; ERIC-HTA 2003 Study Investigators. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24 (4): 663-9.
19. Olivares J, Guillén F, Sánchez JJ, Morales-Olivas FJ. Influencia de la presión arterial y la edad en la función renal. Estudio cuidar el riñón. Nefrología 2003; 23: 137-44.